-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

SMBC Nikko Downgrades Fate Therapeutics to Neutral From Outperform, Adjusts Price Target to $5 From $77

SMBC Nikko Downgrades Fate Therapeutics to Neutral From Outperform, Adjusts Price Target to $5 From $77

MT Newswires · 01/06/2023 03:42